Muhammad Absar et al. 2022. CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML. Journal of Population Therapeutics and Clinical Pharmacology. 29, 02 (Feb. 2022), 311–320. DOI:https://doi.org/10.53555/jptcp.v29i02.4161.